On this page
Reimbursement pathways differ by payer type: Medicare follows National and Local Coverage Determinations, Medicaid is state-administered with variable coverage, and commercial insurers make independent decisions. All pathways require an FDA classification, a reimbursement code, and clinical evidence demonstrating safety and utility. The device's intended use determines which payer is primary.
- Medicare, Medicaid, and commercial insurers operate separate reimbursement systems with different evidence standards and decision timelines; winning coverage from one does not guarantee coverage from another.
- FDA device classification and CPT or HCPCS codes are prerequisites for any reimbursement pathway and must be secured before or concurrent with coverage applications.
- Medicare requires clinical utility and cost-effectiveness data; commercial payers often demand additional health economic models and real-world evidence beyond clinical trials.
- New devices frequently lack reimbursement codes and must request one through the CPT Editorial Panel, a process that takes months and requires formal submission 12 weeks before a panel meeting.
- Coverage decisions are often bundled into existing codes or restricted to specific clinical indications, meaning a device approved by the FDA may not receive separate reimbursement or may face coverage limits.
Medical devices account for 5.2% of total U.S. health spending, representing $173.1 billion in annual expenditures. Yet a device that passes FDA review and reaches the market still faces a second gatekeeping process: reimbursement. Payers, Medicare, Medicaid, and commercial insurers, decide whether they will pay for the device, at what rate, and under what conditions. These decisions are made through separate pathways with different evidence requirements, timelines, and decision-makers. A device company that understands which pathway applies to its product, what evidence each pathway demands, and where to submit can navigate reimbursement more efficiently. A company that does not may spend months building the wrong evidence package or submitting to the wrong decision-maker.
What you'll be able to do
By the end of this guide, you will be able to identify which reimbursement pathway applies to a given device based on its intended use and payer type. You will understand what evidence each pathway requires and at what stage of the reimbursement process. You will know where to find the decision-makers for each payer and what the formal submission process looks like. You will recognize common obstacles, bundling, coding conflicts, off-label restrictions, before they derail a coverage application.
Identify which payer type controls reimbursement for your device
The first step is determining which payer will make the primary reimbursement decision for your device. This depends on the device's intended use and the patient population it serves. A device used in a hospital inpatient setting will be reimbursed by Medicare under a different pathway than one used in an outpatient clinic or a patient's home. The payer type, Medicare, Medicaid, or commercial insurance, then determines the evidence standards, submission process, and timeline.
Medicare pathway
Medicare is the single largest payer for medical devices in the United States. Medicare's coverage authority is established under Section 1862 of the Social Security Act, and coverage decisions flow through the Centers for Medicare and Medicaid Services (CMS). CMS uses FDA device categorization as a factor in making coverage decisions. Critically, Medicare does not pay directly for medical devices. Instead, devices are reimbursed as part of a procedure code or bundled into a facility payment. Understanding whether your device will be paid separately or bundled into an existing code is essential to the reimbursement analysis. Medicare coverage decisions are made at two levels: National Coverage Determinations (NCDs), which apply across all Medicare Administrative Contractors, and Local Coverage Determinations (LCDs), which apply within a specific geographic region. An NCD takes precedence over an LCD.
Medicaid pathway
Medicaid is a joint federal-state program, and coverage decisions are made at the state level. State Medicaid programs are granted flexibility to administer their programs within federal requirements. This means coverage for the same device can vary significantly from state to state. Some states may cover a device immediately after Medicare approval; others may require additional evidence or may not cover it at all. The Medicaid Drug Rebate Program requires state Medicaid programs to cover outpatient drugs produced by participating manufacturers for all medically accepted indications, but this requirement applies to drugs, not devices. For devices, each state sets its own coverage policy. If your device is used across multiple states, you will need to submit coverage requests to each state Medicaid program separately. Timelines and evidence requirements vary by state.
Commercial payer pathway
Commercial insurers, Blue Cross, Aetna, UnitedHealth, and others, develop their own medical policies and are not bound by Medicare National Coverage Determinations or Local Coverage Determinations. Approximately 66.1% of the U.S. population had private health insurance as of 2024. Commercial payers frequently reference Medicare NCD and LCD decisions as a starting point but issue criteria that can be more restrictive, less restrictive, or structured differently. Large national plans often set the de facto market standard; smaller regional plans may follow their lead or develop independent policies. Winning Medicare coverage is necessary but not sufficient for commercial coverage. A device company must submit coverage requests to each major commercial plan separately.
Determine your device's FDA classification and coding category
Before submitting a coverage request to any payer, you must know two things: your device's FDA classification and its reimbursement code. These are prerequisites for reimbursement. Payers use both to understand what the device is, what evidence it has undergone, and how it fits into the existing payment system.
Find the FDA classification
The FDA has established classifications for approximately 1,700 different generic types of devices grouped into 16 medical specialties. Devices are classified into one of three categories based on the level of regulatory control needed to ensure safety and effectiveness. Class I devices are subject to general controls only and most are exempt from premarket submission. Approximately 47% of medical devices are classified as Class I. Class II devices require 510(k) premarket notification pathway and account for approximately 43% of all devices. Class III devices require premarket approval and typically include high-risk implants or life-sustaining devices. To find your device's FDA classification, visit the FDA's Device Classification Database on the FDA website. Search by device name or generic type. The classification will tell you and the payer what level of clinical evidence the device has undergone. A Class I device with only general controls has less clinical validation than a Class II or Class III device, and payers will expect different evidence packages accordingly.
Locate or request a reimbursement code
Reimbursement codes are the mechanism by which payers identify and pay for devices and procedures. There are three coding systems: CPT codes, HCPCS codes, and ICD-10 codes. CPT codes are maintained by the American Medical Association and comprise HCPCS Level I. HCPCS Level II codes are maintained by CMS and include device and supply codes. ICD-10-PCS procedure codes are used by inpatient acute care providers and group to Medicare Severity Diagnosis-Related Groups (MS-DRG) for payment. Medicare Administrative Contractors use ICD-10-CM diagnosis codes to determine benefits and coverage. For outpatient devices and procedures, you will need a CPT or HCPCS code. For inpatient devices, you will need an ICD-10-PCS code. Check whether a code already exists for your device by searching the AMA CPT database or the CMS HCPCS database. If no code exists, you must request one. The process for requesting a new CPT code is formal and time-consuming. The CPT Editorial Panel meets three times per year, and the code application submission deadline is 12 weeks prior to the panel meeting. The CPT Editorial Panel consists of 17 experts. Medical device and technology companies, payers, and other interested parties may submit requests for changes to the CPT code set. You will need to provide clinical evidence that the device is distinct from existing codes, that it is used frequently enough to warrant a separate code, and that it has clinical utility. If your code request is denied, you may be bundled into an existing code, meaning your device will be paid at the rate of that code rather than receiving separate reimbursement. This is a common obstacle and should be anticipated in your reimbursement strategy.
Gather clinical evidence required by the payer
Each payer type has different standards for the clinical evidence it will accept. Understanding what evidence is required before you begin gathering it will save time and money. Evidence that satisfies Medicare may not satisfy a commercial payer, and vice versa.
Medicare evidence standards
Medicare requires clinical utility and cost-effectiveness data. Clinical utility means the device provides a clinically meaningful benefit to Medicare beneficiaries. Cost-effectiveness means the device's benefit justifies its cost relative to existing alternatives. Medicare distinguishes between coverage decisions and non-coverage decisions. A coverage decision means Medicare will pay for the device. A non-coverage decision means Medicare will not pay for it. A non-coverage decision does not mean the device is unsafe or ineffective; it may mean Medicare believes the evidence is insufficient to establish clinical utility or that the device is experimental. CMS uses FDA categorization as a factor in making coverage decisions. Category A devices are experimental, the absolute risk has not been established and the FDA is unsure whether the device type can be safe and effective. Category B devices are nonexperimental or investigational, either the incremental risk is the primary question or it is known that the device type can be safe and effective. A Category A device faces a higher evidentiary bar than a Category B device. Medicare may offer Coverage with Evidence Development (CED), a paradigm whereby Medicare covers items or services only in the context of a clinical study. CED is authorized under Section 1862(a)(1)(E) of the Social Security Act. This pathway allows Medicare to cover a device while requiring the manufacturer to collect additional real-world evidence. CMS issued proposed CED guidance on June 22, 2023. If your device is approved for CED, you will be required to enroll patients in a registry or observational study and submit data on outcomes, safety, and utilization.
Commercial payer evidence standards
Commercial payers often require health economic models and real-world data alongside clinical trials. A randomized controlled trial demonstrating clinical efficacy may not be sufficient. Commercial payers want to know: Does the device work in routine clinical practice, not just in a controlled trial? What is the cost per quality-adjusted life year (QALY) or cost per health outcome achieved? How does the device compare to existing alternatives in real-world settings? Commercial payers frequently request health economic models that project long-term outcomes and costs. They may also request real-world evidence from electronic health records, claims databases, or registries. If your device is new and lacks real-world data, commercial payers may approve coverage on a conditional basis, requiring you to submit real-world evidence within a specified timeframe. If the evidence does not support the initial coverage decision, the payer may withdraw or restrict coverage.
Submit a coverage request to the appropriate decision-maker
Once you have identified the payer pathway, secured a reimbursement code, and gathered the required clinical evidence, you are ready to submit a coverage request. The submission process, timeline, and decision criteria differ by payer type.
Medicare submissions
Medicare coverage requests are submitted to either CMS (for a National Coverage Determination) or to the relevant Medicare Administrative Contractor (for a Local Coverage Determination). An NCD applies nationwide; an LCD applies within a specific geographic region. Most devices will pursue an LCD first because the timeline is shorter and the geographic scope may be sufficient to establish market access. NCD requests are accepted by CMS on a rolling basis. A complete formal NCD request must include clearly identified benefit category, supporting evidence and documentation, information on usefulness and benefit to the Medicare population, and complete explanation of design, purpose, and method. Medicare Administrative Contractors will review LCD requests within 60 calendar days and notify the requestor whether the request is complete or incomplete. If the request is incomplete, you will have an opportunity to submit additional information. The review process typically takes 6 to 12 months from submission to decision. To identify the correct Medicare Administrative Contractor for your device, visit the CMS website and search by state or region. The MAC's website will have a submission portal and detailed instructions for the evidence package required.
Commercial payer submissions
Large commercial payers have formal submission portals and standardized evidence requirements. Visit the payer's website and search for 'coverage request' or 'medical policy submission.' Most large plans require submission of a health economic model, clinical evidence, and a comparison to existing alternatives. Smaller commercial plans may not have formal submission processes; they may instead follow the coverage decisions of larger competitors or require submission through their medical director's office. A commercial coverage playbook requires securing a HCPCS or CPT code, building an evidence dossier, winning payer medical-policy adoption, and managing prior authorization. After a commercial payer approves coverage, the device will be subject to prior authorization requirements, the payer will require the ordering physician to submit clinical justification before reimbursement is approved. This is standard practice and should be anticipated in your market access strategy.
Interpret the coverage decision and reimbursement rate
A coverage decision is not the same as a reimbursement rate. Coverage means the payer will pay for the device under specified conditions. The reimbursement rate is the amount the payer will pay. A device can be covered but reimbursed at a rate so low that it is not economically viable. Understand the distinction. A Medicare coverage decision specifies the indication (the medical condition for which the device is approved), any patient population restrictions, and any documentation requirements. For example, a coverage decision might state: 'Device X is covered for patients with indication Y who have failed conservative treatment and meet criteria Z.' This means the device is covered only for that specific population. Use of the device outside that indication is off-label and will not be reimbursed. The reimbursement rate for inpatient devices is determined by the MS-DRG. Medicare IPPS primarily pays a predetermined rate intended to cover the operating and capital costs of furnishing an acute hospital inpatient stay. For fiscal year 2026, the Medicare IPPS operating base rate is $6,753 and the capital base rate is $524. In fiscal year 2023, the Medicare program and its beneficiaries spent $109.3 billion on inpatient services covered under IPPS. Medicare pays a fixed, bundled prospective rate under IPPS determined by the patient's assigned Medicare Severity Diagnosis-Related Group (MS-DRG). This means the hospital receives a single payment for the entire inpatient stay, regardless of the cost of the device. If your device is expensive, the hospital may absorb the cost or may negotiate a volume discount with the manufacturer. For outpatient devices, the reimbursement rate is determined by the CPT or HCPCS code. The rate is set by CMS and varies by geographic region and payer. Commercial payers often set their rates as a percentage of Medicare's rate. Request the reimbursement rate from the payer before finalizing your market access strategy.
Recognize common reimbursement obstacles
Certain barriers appear repeatedly in device reimbursement. Recognizing them early allows you to address them proactively rather than discovering them after a coverage denial.
Insufficient clinical evidence
Payers may request additional studies or real-world data before coverage. This is common for devices that are new or that lack long-term outcome data. If a payer requests additional evidence, ask specifically what data would satisfy the requirement. Request a timeline for resubmission. Some payers will approve coverage contingent on the submission of real-world evidence within 12 to 24 months. If the evidence is not submitted or does not support the initial decision, coverage may be withdrawn. Plan for this scenario by building a registry or claims-based study into your market access strategy from the beginning.
Bundling and coding conflicts
New devices are sometimes bundled into existing codes, eliminating separate reimbursement. This happens when a payer determines that the device is an incremental improvement over an existing device and does not warrant a separate code or separate payment. For example, if a new surgical instrument is considered a minor variation of an existing instrument, it may be bundled into the existing CPT code. The result is that your device is paid at the rate of the existing code, not at a rate that reflects its cost or value. To avoid this, build a strong case for why your device is distinct from existing alternatives. Document the clinical differences and the incremental benefit. If bundling occurs, you may appeal the decision or pursue a separate code through the CPT Editorial Panel.
Off-label use and coverage gaps
Coverage is tied to specific indications. A device approved by the FDA for indication A may not be reimbursed for indication B, even if physicians believe it is clinically appropriate. This is an off-label use. Payers will not reimburse off-label use unless the manufacturer has submitted evidence and won a separate coverage decision for that indication. If your device has multiple potential indications, prioritize which indication to pursue first in your reimbursement strategy. Winning coverage for one indication may make it easier to win coverage for others, but each indication requires its own evidence package and coverage submission. Anticipate coverage gaps by mapping all intended uses of your device and planning reimbursement submissions for each.
Do this automatically
Determining the correct reimbursement pathway requires identifying your payer type, understanding FDA classification requirements, and preparing evidence packages tailored to each pathway's standards, a process that involves multiple submissions, documentation reviews, and timeline management across Medicare, Medicaid, and commercial insurers. Software platforms can automate the tracking of these parallel pathways, manage submission requirements by payer type, and maintain the evidence documentation needed for each coverage decision. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
